These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 24217539

  • 1. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 2. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

  • 3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 4. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, Bal C.
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [Abstract] [Full Text] [Related]

  • 5. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M.
    Contrast Media Mol Imaging; 2018 Jul; 2018():2340389. PubMed ID: 29681780
    [Abstract] [Full Text] [Related]

  • 6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 7. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, Bal C.
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [Abstract] [Full Text] [Related]

  • 8. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S.
    J Nucl Med; 2024 Oct 01; 65(10):1591-1596. PubMed ID: 39266292
    [Abstract] [Full Text] [Related]

  • 9. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.
    Cancer; 2008 Jun 01; 112(11):2447-55. PubMed ID: 18383518
    [Abstract] [Full Text] [Related]

  • 10. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
    Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P.
    Clin Imaging; 2020 Nov 01; 67():113-116. PubMed ID: 32559681
    [Abstract] [Full Text] [Related]

  • 11. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.
    Sampathirao N, Basu S.
    J Nucl Med Technol; 2017 Mar 01; 45(1):34-41. PubMed ID: 28154019
    [Abstract] [Full Text] [Related]

  • 12. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2008 Aug 01; 35(8):1431-8. PubMed ID: 18418596
    [Abstract] [Full Text] [Related]

  • 13. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
    Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ.
    Head Neck; 2016 Apr 01; 38(4):E76-80. PubMed ID: 26275126
    [Abstract] [Full Text] [Related]

  • 14. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M, Shamseddine A, Panagiotidis E, Jreige M, Mukherji D, Assi R, Abousaid R, Ibrahim T, Haddad MM, Vinjamuri S.
    Nucl Med Commun; 2017 Feb 01; 38(2):170-177. PubMed ID: 27922538
    [Abstract] [Full Text] [Related]

  • 15. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug 01; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.
    Invest Radiol; 2014 Jan 01; 49(1):7-14. PubMed ID: 24002080
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
    Sharma A, Das CJ, Makharia GK, Arora G, Kumar R.
    Clin Nucl Med; 2020 Nov 01; 45(11):848-853. PubMed ID: 32657875
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan 01; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A, Rufini V, Brizi MG, Iacovazzo D, Larghi A, Massara RM, Petrone G, Poscia A, Treglia G, De Marinis L, Giordano A, Rindi G, Bonomo L.
    Pancreas; 2016 Mar 01; 45(3):345-54. PubMed ID: 26418904
    [Abstract] [Full Text] [Related]

  • 20. A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT.
    Treglia G, Salomone E, Petrone G, Giaccari A, Rindi G, Rufini V.
    Clin Nucl Med; 2013 Jul 01; 38(7):e306-8. PubMed ID: 23486330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.